GITRL-armed Delta-24-RGD oncolytic adenovirus prolongs survival and induces anti-glioma immune memory
Abstract
Viroimmunotherapy is evolving as a strong alternative for the standard treatment of malignant gliomas. Promising results from a recent clinical trial testing the anticancer effect of Delta-24-RGD in patients with glioblastoma suggested the induction of antitumoral immunity after viral administration. To further enhance the anti-glioma immune effect, we have armed Delta-24-RGD with the costimulatory ligand GITRL (Delta-24-GREAT [Glucocorticoid Receptor Enhanced Activity of T cells]).
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- May 01, 2019
- Source ID
- 10.1093/noajnl/vdz009
Entities
People
- Candelaria Gomez-Manzano
- Dong Ho Shin
- Frederick F Lang
- Gilbert Youssef
- Hong Jiang
- James P. Harris
- Joy Gumin
- Juan Fueyo
- Marta M Alonso
- Sheetal Phadnis
- Teresa T Nguyen
- Xuejun Fan
- Yisel Rivera-molina
Organizations
- Cancer Prevention and Research Institute of Texas
- Clínica Universidad de Navarra
- National Cancer Institute
- National Institutes of Health
- The University of Texas MD Anderson Cancer Center
- United States Department of Defense
- University of Navarre
- University of Texas at Austin